Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Research & Development (2016 - 2025)

Historic Research & Development for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $6.4 million.

  • Standard Biotools' Research & Development fell 840.18% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.5 million, marking a year-over-year increase of 7405.59%. This contributed to the annual value of $62.4 million for FY2024, which is 14052.34% up from last year.
  • Per Standard Biotools' latest filing, its Research & Development stood at $6.4 million for Q3 2025, which was down 840.18% from $6.2 million recorded in Q2 2025.
  • Over the past 5 years, Standard Biotools' Research & Development peaked at $40.6 million during Q4 2024, and registered a low of $6.2 million during Q2 2023.
  • Moreover, its 5-year median value for Research & Development was $8.5 million (2022), whereas its average is $10.3 million.
  • Per our database at Business Quant, Standard Biotools' Research & Development plummeted by 5094.4% in 2023 and then skyrocketed by 48792.88% in 2024.
  • Over the past 5 years, Standard Biotools' Research & Development (Quarter) stood at $8.5 million in 2021, then decreased by 13.07% to $7.4 million in 2022, then dropped by 6.95% to $6.9 million in 2023, then soared by 487.93% to $40.6 million in 2024, then plummeted by 84.35% to $6.4 million in 2025.
  • Its Research & Development was $6.4 million in Q3 2025, compared to $6.2 million in Q2 2025 and $11.3 million in Q1 2025.